Hoxprin 60

Hoxprin 60 is an anticoagulant injection that consists of Enoxaparin Sodium 60mg/0.6mL. Enoxaparin comes from the class of medicines which is called low molecular weight heparins (LMWHs). It is used to help avoid and treat blood clots in ideal clinical situations. The 60mg/0.6mL presentation is equal to a concentration of 100mg/mL and is usually supplied as a single dose prefilled syringe.

Composition:
Enoxaparin Sodium Injection IP – 60 mg/0.6 mL

Uses and Therapeutic Benefits

Hoxprin 60 may be prescribed for the prevention of deep vein thrombosis (DVT) in patients who are at increased risk of developing blood clots, including certain patients undergoing abdominal, hip-replacement, or knee-replacement surgery and individuals with severely restricted mobility during acute illness. Enoxaparin is also used in the treatment of acute DVT, with or without pulmonary embolism, in accordance with the prescribed treatment regimen.

In selected cardiovascular conditions, enoxaparin may also be used to reduce the risk of ischemic complications associated with unstable angina and non-ST-elevation myocardial infarction (NSTEMI). It also has indications in the management of certain patients with ST-segment elevation myocardial infarction (STEMI).

How Hoxprin 60 Works?

Enoxaparin is an anticoagulant that works primarily by enhancing the activity of antithrombin, thereby inhibiting clotting factors involved in the coagulation process, particularly Factor Xa. By reducing the formation and progression of blood clots, it helps lower the risk of potentially serious thromboembolic complications.

Hoxprin 60 is generally administered by subcutaneous injection, with the exact dose and treatment duration determined by the treating physician. Dosage may vary depending on the medical indication, body weight, kidney function, age, and individual risk factors. Patients should never adjust the dose themselves.

Precautions and Safety Information

Because enoxaparin affects blood clotting, bleeding is an important potential risk during treatment. Patients should promptly report unusual bruising, prolonged bleeding, blood in urine or stools, vomiting blood, or other signs of significant bleeding. Platelet counts may also need monitoring during therapy.

Hoxprin 60 should not be used in patients with active major bleeding, certain recent or active cases of immune-mediated heparin-induced thrombocytopenia (HIT), or known hypersensitivity to enoxaparin, heparin, or pork products.

Conclusion

Hoxprin 60 (Enoxaparin Sodium Injection IP 60 mg/0.6 mL) is an injectable LMWH formulation intended for medically supervised prevention and treatment of thromboembolic disorders. Its anticoagulant action makes it an important therapeutic option in situations where prevention or management of blood clots is clinically indicated. As an anticoagulant injection, it should be administered and monitored strictly according to a qualified healthcare professional’s instructions.